Boston Scientific approves 2026 restructuring plan with $700M-$800M pre-tax charges

BOSTON SCIENTIFIC CORP

Board approved 2026 Restructuring Plan on July 21, 2026; expected to be substantially completed by end of 2029.
Estimated total pre-tax charges of $700M-$800M, with $600M-$700M in cash outlays; annual pre-tax expense reduction of ~$500M.
Charges include transfer costs ($300M-$350M), termination benefits ($275M-$300M), and other costs ($125M-$150M).
Headcount reductions expected, but new jobs created in growth areas; savings to be reinvested in strategic growth initiatives.
Activities include supply chain optimization, transferring production lines, and functional transformation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.